Skip to main content

Table 2 The multinomial logistic regression analysis of NAR

From: Impact of glucocorticoids on the efficacy of neoadjuvant chemoradiotherapy and survival of patients with locally advanced rectal cancer: a retrospective study

Variable

Mid-NAR vs Low-NAR

High-NAR vs Low-NAR

High-NAR vs Mid-NAR

OR

95% CL for OR

P

OR

95% CL for OR

P

OR

95% CL for OR

P

Lower

Upper

Lower

Upper

Lower

Upper

Age

1.016

1.000

1.032

0.057

1.001

0.982

1.021

0.895

0.986

0.967

1.004

0.134

Sex (Female: Male)

0.738

0.524

1.038

0.081

0.710

0.463

1.087

0.115

0.962

0.625

1.480

0.860

CEA

1.011

1.002

1.020

0.016

1.008

0.999

1.017

0.078

0.997

0.994

1.001

0.143

CA199

1.002

0.999

1.005

0.125

1.003

1.000

1.006

0.035

1.001

0.999

1.003

0.276

Tumor Location

 High: Low

4.245

1.484

12.146

0.007

2.394

0.677

8.471

0.176

0.564

0.204

1.561

0.270

 Middle: Low

1.416

1.008

1.990

0.045

1.225

0.805

1.863

0.344

0.865

0.566

1.320

0.500

 Chemotherapy before NCRT (No: Yes)

1.030

0.434

2.446

0.946

2.479

0.723

8.504

0.149

2.407

0.698

8.296

0.164

CCT regimen

 Xelox: Xeloda

0.727

0.463

1.141

0.166

0.929

0.544

1.587

0.788

1.278

0.749

2.183

0.368

 De Gramont:Xeloda

1.068

0.257

4.428

0.928

0.728

0.091

5.843

0.765

0.682

0.087

5.367

0.716

 FOLFOX4: Xeloda

0.498

0.159

1.557

0.231

0.798

0.209

3.055

0.742

1.604

0.410

6.267

0.497

 SIB to GTV (No: Yes)

1.114

0.429

2.892

0.825

0.867

0.274

2.743

0.808

0.779

0.257

2.362

0.659

Radiotherapy technology

 VAMT:3D-CRT

0.773

0.309

1.937

0.583

0.508

0.148

1.742

0.281

0.657

0.183

2.361

0.520

 IMRT:3D-CRT

1.360

0.863

2.143

0.185

0.916

0.539

1.557

0.746

0.674

0.394

1.152

0.149

 Days of radiotherapy

1.005

0.964

1.047

0.831

1.001

0.950

1.055

0.972

0.996

0.946

1.050

0.893

 Interval between radiotherapy and surgery

0.997

0.982

1.011

0.645

0.991

0.972

1.011

0.370

0.995

0.975

1.014

0.586

 Number of lymph nodes dissected

1.033

1.006

1.060

0.017

1.091

1.058

1.124

 < 0.001

1.056

1.026

1.087

 < 0.001

 GCs use (No: Yes)

0.615

0.420

0.901

0.013

0.563

0.352

0.900

0.016

0.915

0.579

1.447

0.704

  1. Abbreviations: OR odds ratio, CL confidence limits, NAR neoadjuvant rectal score, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19–9, NCRT neoadjuvant chemoradiotherapy, CCT Concurrent chemotherapy, SIB simultaneous integrated boost, GTV gross tumor volume, IMRT intensity modulated radiation therapy, 3D-CRT 3-dimensional conventional radiotherapy, VAMT volumetric modulated arc therapy, GCs glucocorticoid
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us